JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Aandelen Lijst・Becton Dickinson and Co

Becton Dickinson and Co

Gesloten

SectorGezondheidszorg

144.15 -1.48

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

142.93

Max

146.3

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.3B 382M
Verkoop	-639M 5.3B
K/W Sectorgemiddelde	24.546 67.147
EPS	2.91
Dividendrendement	2.74
Winstmarge	7.273
Werknemers	70,000
EBITDA	-86M 1.2B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+23.42% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	2.74% 2.36%
Volgende Winsten	7 mei 2026
Volgende dividenddatum	30 jun 2026
Volgende Ex Dividend datum	9 jun 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-15B 43B
Vorige openingsprijs	145.63
Vorige sluitingsprijs	144.15

Nieuwssentiment

By Acuity

25%

75%

72 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

167 / 206.99 Steun & Weerstand

Becton Dickinson and Co Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 aug 2025, 11:19 UTC

Winsten

Becton Dickinson Boosts Outlook as 3Q Results Beat Estimates

14 jul 2025, 14:26 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 jul 2025, 11:08 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14 jul 2025, 10:37 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

7 aug 2025, 10:32 UTC

Winsten

Becton Dickinson Expects to Complete Remaining $250M of $1B Share-Buyback Commitment by End FY25 >BDX

7 aug 2025, 10:31 UTC

Winsten

Becton Dickinson Backs FY25 View of Rev $21.8B-$21.9B >BDX

7 aug 2025, 10:31 UTC

Winsten

Becton Dickinson Had Seen FY25 Adjusted EPS $14.06-$14.34 >BDX

7 aug 2025, 10:30 UTC

Winsten

Becton Dickinson Raises FY25 View To Adj EPS $14.30-Adj EPS $14.45 >BDX

7 aug 2025, 10:30 UTC

Winsten

Becton Dickinson 3Q Adj EPS $3.68 >BDX

7 aug 2025, 10:30 UTC

Winsten

Becton Dickinson 3Q Net $574M >BDX

7 aug 2025, 10:30 UTC

Winsten

Becton Dickinson 3Q Rev $5.51B >BDX

7 aug 2025, 10:30 UTC

Winsten

Becton Dickinson 3Q EPS $2.00 >BDX

15 jul 2025, 18:32 UTC

Acquisities, Fusies, Overnames

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 jul 2025, 18:31 UTC

Acquisities, Fusies, Overnames

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 jul 2025, 16:12 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 jul 2025, 15:06 UTC

Acquisities, Fusies, Overnames

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 jul 2025, 14:11 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 jul 2025, 10:53 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 jul 2025, 10:22 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 jul 2025, 10:22 UTC

Acquisities, Fusies, Overnames

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 jul 2025, 10:22 UTC

Acquisities, Fusies, Overnames

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 jul 2025, 10:21 UTC

Acquisities, Fusies, Overnames

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 jul 2025, 10:20 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 jul 2025, 10:19 UTC

Acquisities, Fusies, Overnames

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 jul 2025, 10:19 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 jul 2025, 10:18 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 jul 2025, 10:18 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 jul 2025, 10:17 UTC

Acquisities, Fusies, Overnames

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 jul 2025, 10:16 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 jul 2025, 10:16 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

Peer Vergelijking

Prijswijziging

Becton Dickinson and Co Prognose

Koersdoel

By TipRanks

23.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 180.58 USD 23.42%

Hoogste 221 USD

Laagste 157 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Becton Dickinson and Co - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Becton Dickinson and Co - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

167 / 206.99Steun & Weerstand

Bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

72 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.